Please check your internet connection and try again.
# Atorvastatin
## Overview
Atorvastatin is a statin (HMG-CoA reductase inhibitor) used to lower cholesterol levels in the blood. It reduces the production of cholesterol by the liver and increases the clearance of LDL cholesterol from the blood.
## Primary Indications
* Hyperlipidemia (various types)
* Prevention of cardiovascular events in patients with risk factors for coronary heart disease.
## Adult Dosing
* **Hyperlipidemia:** Usual starting dose is 10-20 mg once daily. Usual maintenance dose is 10-80 mg once daily.
* **Cardiovascular Risk Reduction:** 10-80 mg once daily.
* **Maximum Dose:** 80 mg once daily.
## Pediatric Dosing
* **Ages 10-17 years with Heterozygous Familial Hypercholesterolemia:** 10 mg once daily, titrate up to 20 mg daily (max).
## Dose Adjustments
* **Renal Impairment:** No dose adjustment is typically needed.
* **Hepatic Impairment:** Use with caution. Patients with active liver disease should generally not use atorvastatin.
## Contraindications
* Active liver disease
* Unexplained persistent elevations of serum transaminases
* Hypersensitivity to atorvastatin or any component of the formulation
## Adverse Effects
* **Common:** Myalgia, arthralgia, diarrhea, nausea, headache.
* **Serious:** Myopathy, rhabdomyolysis (with or without acute kidney injury), liver dysfunction, immune-mediated necrotizing myopathy (IMNM).
## Key Drug Interactions
* **CYP3A4 Inhibitors (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir):** May increase atorvastatin levels, increasing the risk of myopathy. Dose reduction of atorvastatin may be necessary.
* **CYP3A4 Inducers (e.g., rifampin):** May decrease atorvastatin levels.
* **Gemfibrozil, Fenofibrate:** Increased risk of myopathy and rhabdomyolysis. Co-administration generally not recommended.
* **Digoxin:** May increase digoxin levels. Monitor digoxin levels.
* **Oral Contraceptives:** May increase ethinyl estradiol and norgestrel levels.
## Monitoring
* **Baseline:** Liver function tests (ALT, AST), lipid panel.
* **Routine:** Lipid panel (typically 4-12 weeks after initiation or dose change, then as clinically indicated). Monitor for signs and symptoms of myopathy (muscle pain, tenderness, weakness). Consider CK levels if myopathy is suspected.
## Clinical Pearls
* Atorvastatin is generally taken once daily, with or without food.
* The risk of myopathy is dose-dependent and increased with concomitant use of other drugs that inhibit atorvastatin metabolism.
* Patient education regarding reporting of muscle pain or weakness is crucial.
* Risk of IMNM is rare but serious and may occur after prolonged use.
***
*Disclaimer: This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult the most current prescribing information and relevant guidelines for definitive patient care decisions.*
